CRVS Corvus Pharmaceuticals Inc: רווח נקי למניה ב-12 החודשים האחרונים

Corvus Pharmaceuticals Inc (CRVS) - לוגו תאגידי

The EPS (TTM) price visualization for Corvus Pharmaceuticals (CRVS), which specializes in lymphoma therapy, demonstrates a figure of -273.40. Corvus Pharmaceuticals (CRVS) independently tests oncology molecules while limiting itself to scientific collaborations. Growth relies on socrelitinib trials and merger potential; however, the lack of proprietary revenue and dependence on external investments create significant risks in the event of R&D failures.

CRVS - רווח נקי למניה (EPS TTM) corvuspharma.com בטווח 11.02.2024 - 18.11.2026

CRVS (Corvus Pharmaceuticals, Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

- מחיר ותחזית קונצנזוס למחירים:
ניתוח ראשוני של החברה:CRVS, Corvus Pharmaceuticals, Inc.
מוצר עיקרי של corvuspharma.com

Corvus Pharmaceuticals (CRVS) focuses on developing precision immunotherapy to combat oncological diseases through T-cell activation. By analyzing the EPS YoY TTM trend, an investor can observe the percentage change in earnings per share over a twelve-month period relative to the previous year. This indicator measures the efficiency of monetizing scientific developments and the pace of reducing operating losses. Steady growth in this metric confirms the biotech's transition from the R&D stage toward commercial sustainability.